n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
ARIAD To Host Analyst & Investor Day In New York City

ARIAD To Host Analyst & Investor Day In New York City

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host an Analyst & Investor Day for its research analysts and institutional investors on Friday, June 17 at 8:30 a.

Today's Weak On High Volume Stock: ARIAD Pharmaceuticals (ARIA)

Today's Weak On High Volume Stock: ARIAD Pharmaceuticals (ARIA)

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a weak on high relative volume candidate

Cancer Drug Stocks: The Winners and Losers From ASCO 2016

Cancer Drug Stocks: The Winners and Losers From ASCO 2016

A summary (and somewhat subjective) breakdown of winners and losers from the American Society of Clinical Oncology annual meeting.

ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate And 12.9-Month Median Progression-Free Survival In ALTA Study

ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate And 12.9-Month Median Progression-Free Survival In ALTA Study

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in patients who had...

ARIAD Presents Data From Mutational Profiling In Crizotinib-Resistant Patients Treated With Investigational Medicine Brigatinib Showing Similar Response Rates In Patients With And Without Secondary ALK Mutations

ARIAD Presents Data From Mutational Profiling In Crizotinib-Resistant Patients Treated With Investigational Medicine Brigatinib Showing Similar Response Rates In Patients With And Without Secondary ALK Mutations

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced clinical data from an analysis aimed at characterizing the activity of its investigational tyrosine kinase inhibitor (TKI), brigatinib, in patients with...

ARIAD Presents Long-Term Phase 1/2 Trial Follow Up On Investigational Drug Brigatinib With Median Time On Treatment Of 17 Months In ALK+ NSCLC Patients

ARIAD Presents Long-Term Phase 1/2 Trial Follow Up On Investigational Drug Brigatinib With Median Time On Treatment Of 17 Months In ALK+ NSCLC Patients

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor (TKI), brigatinib, in patients with anaplastic lymphoma kinase-positive (ALK+)...

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Post-Market Leader Stock

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a post-market leader candidate

ARIAD Completes The Sale Of Its European Operations And Out-License Of European Rights To Iclusig®

ARIAD Completes The Sale Of Its European Operations And Out-License Of European Rights To Iclusig®

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has completed the sale of its European operations to Incyte Corporation and entered into the previously announced license agreement for Incyte to...

ARIAD To Present At The Jefferies 2016 Global Healthcare Conference

ARIAD To Present At The Jefferies 2016 Global Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Jefferies 2016 Global Healthcare Conference being held in New York City.

Ariad Pharmaceuticals Is Nearly Done Building Base Pattern

We should go long ARIA on available weakness and risk below $6.50.

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate

ARIAD Announces Initiation Of Phase 1/2 Clinical Trial Of AP32788, An Investigational Oral Inhibitor Of EGFR And HER2, In Patients With Non-Small Cell Lung Cancer

ARIAD Announces Initiation Of Phase 1/2 Clinical Trial Of AP32788, An Investigational Oral Inhibitor Of EGFR And HER2, In Patients With Non-Small Cell Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced initiation of the Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted therapy for patients with...

Insider Trading Alert - DEPO, ARIA And ROG Traded By Insiders

Insider Trading Alert - DEPO, ARIA And ROG Traded By Insiders

Stocks with insider trader activity include DEPO, ARIA and ROG

ARIAD Announces Appointment Of Jennifer L. Herron As Chief Commercial Officer

ARIAD Announces Appointment Of Jennifer L. Herron As Chief Commercial Officer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Jennifer L.

ARIAD Announces Pricing And Reimbursement For Iclusig In France

ARIAD Announces Pricing And Reimbursement For Iclusig In France

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that negotiations with the Economic Committee on Health Care Products in France regarding pricing and reimbursement for Iclusig ® (ponatinib) have now...

ARIAD Announces Data Presentations At The 2016 ASCO Annual Meeting

ARIAD Announces Data Presentations At The 2016 ASCO Annual Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, and Iclusig ® (ponatinib) will be presented at the...

Biotech Gets a Lifeline

Biotech Gets a Lifeline

Solid earnings and the start of some M&A activity may be just what this sector needs to rise.

ARIAD Reports First Quarter 2016 Financial Results And Progress On Strategic Review

ARIAD Reports First Quarter 2016 Financial Results And Progress On Strategic Review

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the first quarter of 2016, including revenue from sales of Iclusig ® (ponatinib).

Incyte Buys European Business Hub From Ariad Pharma

Incyte Buys European Business Hub From Ariad Pharma

Incyte chose to buy a turnkey European commercial operation instead of building one.

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a weak on high relative volume candidate

Insider Trading Alert - DWRE, ARIA And PTC Traded By Insiders

Insider Trading Alert - DWRE, ARIA And PTC Traded By Insiders

Stocks with insider trader activity include DWRE, ARIA and PTC

ARIAD To Webcast Conference Call On First Quarter 2016 Financial Results

ARIAD To Webcast Conference Call On First Quarter 2016 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its first quarter 2016 financial results on Tuesday, May 10, 2016, before the market opens.

ARIAD Announces Results Of Preclinical Studies On AP32788 At The Annual Meeting Of The American Association For Cancer Research

ARIAD Announces Results Of Preclinical Studies On AP32788 At The Annual Meeting Of The American Association For Cancer Research

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of comprehensive preclinical studies on its investigational tyrosine kinase inhibitor (TKI), AP32788, at the American Association for Cancer...

ARIAD Presents Updated Phase 1/2 Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer

ARIAD Presents Updated Phase 1/2 Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib, in patients with advanced malignancies, including anaplastic lymphoma...

ARIAD Announces Initiation Of Randomized, First-Line Phase 3 Trial Of Brigatinib In Treatment Of ALK-Positive Non-Small Cell Lung Cancer

ARIAD Announces Initiation Of Randomized, First-Line Phase 3 Trial Of Brigatinib In Treatment Of ALK-Positive Non-Small Cell Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the initiation of a randomized, first-line Phase 3 clinical trial of brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, in adult...

ARIAD Announces Reduction In Workforce As Part Of Ongoing Company-Wide Strategic Review

ARIAD Announces Reduction In Workforce As Part Of Ongoing Company-Wide Strategic Review

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it is reducing approximately 25 percent of its headquarter positions.

ARIAD Reports Inducement Grant To New Chief Financial Officer

ARIAD Reports Inducement Grant To New Chief Financial Officer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported the grant of an inducement award to its new Chief Financial Officer, Manmeet S.

Manmeet S. Soni (Photo: Business Wire)

Manmeet S. Soni (Photo: Business Wire)

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Manmeet S.

ARIAD To Present At Upcoming Investor Conferences

ARIAD To Present At Upcoming Investor Conferences

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company's business at two upcoming investor conferences:...

First Week of April 15th Options Trading For ARIAD Pharmaceuticals (ARIA)

First Week of April 15th Options Trading For ARIAD Pharmaceuticals (ARIA)

Investors in ARIAD Pharmaceuticals, Inc. saw new options become available this week, for the April 15th expiration.